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Background and Objectives: Primary colonic lymphoma (PCL) is rare, heterogeneous,
and presents a therapeutic challenge for surgeons. Optimal treatment strategies are
difficult to standardize, leading to variation in therapy. Our objective was to describe
the patient characteristics, short‐term outcomes, and five‐year survival of patients
undergoing nonpalliative surgery for PCL.
Methods: We performed a retrospective cohort analysis in the National Cancer
Database. Included patients underwent surgery for PCL between 2004 to 2014.
Patients with metastases and palliative operations were excluded. Univariate
predictors of overall survival were analyzed using multivariable Cox proportional
hazard analysis.
Results: We identified 2153 patients. Median patient age was 68. Diffuse large B‐cell
lymphoma accounted for 57% of tumors. 30‐ and 90‐Day mortality were high (5.6%
and 11.1%, respectively). Thirty‐nine percent of patients received adjuvant
chemotherapy. For patients surviving 90 days, 5‐year survival was 71.8%.
Chemotherapy improved survival (surgery+chemo, 75.4% vs surgery, 68.6%;
P = .01). Adjuvant chemotherapy was associated with overall survival after controlling
for age, comorbidity, and lymphoma subtype (HR 1.27; 95% CI, 1.07‐1.51; P = .01).
Conclusions: Patients undergoing surgery for PCL have high rates of margin positivity
and high short‐term mortality. Chemotherapy improves survival, but <50% receive it.
These data suggest the opportunity for improvement of care in patients with PCL.
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1 | INTRODUCTION
Primary gastrointestinal (GI) lymphoma is a rare heterogeneous
malignancy arising in the GI tract as a primary extranodal tumor. The
colorectum accounts for 6% to 12% of GI lymphoma, but among
colonic neoplasms primary colonic lymphoma (PCL) is a rare entity:
representing <1% of all colorectal tumors.1 The vast majority of PCL
arises from the B‐cell lineage, but as they may arise at any stage of
maturation of T‐cells, B‐cells, or Natural killer (NK) cells, there exists
a large number of potential histologic subtypes.2 Treatment of
lymphoma of the colon or rectum may include chemotherapy,
radiation, and surgery.
The outcomes of, and indications for, surgical resection in
colorectal lymphoma remain unclear. Multi‐institutional studies
indicate 48% to 61% of patients with PCL have surgery.3-5 Surgery
provides a definitive diagnosis, palliates symptoms, may prevent
tumor perforation on chemotherapy, provides local control for
aggressive disease, and may be the definitive treatment for
chemotherapy‐resistant indolent histologic subtypes. However,
surgery is morbid, does not treat systemic disease, and does not
definitively improve survival.6,7 Due to the rarity of PCL, the bulk of
the available surgical data is retrospective and combines multiple GI
sites, pathologic stages, and histologic subtypes.3,4 Therefore, when a
surgical approach, elective or urgent, is chosen for a PCL patient,
there is a knowledge gap in the expected short and long term
outcome of the patient.
The National Cancer Database (NCDB) captures approximately
70% of newly diagnosed cancers in the United States and
demonstrates concordance with most population‐based registries.8
Therefore, the NCDB is a platform for interrogating “real world”
outcomes of surgical patients with PCL. The purpose of this study is
to provide a thorough, modern, multi‐institutional description of the
short and long terms outcomes of patients undergoing nonpalliative
surgical treatment of PCL to inform treatment decisions and patient
counseling. We hypothesize that the addition of adjuvant chemother-
apy will be associated with increased survival.
2 | METHODS
2.1 | Data source
Data for this study was extracted from the Participant User File of
the NCDB. The NCDB is a joint project between the American
College of Surgeons’ Commission on Cancer (CoC) and the American
Cancer Society.9,10 The NCDB gathers data from more than 1700
CoC‐accredited centers across the United States and Puerto Rico.
The NCDB is estimated to capture approximately 70% of new cancer
diagnoses and now contains more than 30 million patient files.
2.2 | Study design
This project was reviewed and deemed exempt by the Vanderbilt
University Medical Center Institutional Review Board (Protocol
161707). We conducted a retrospective, cohort analysis of a
prospectively maintained database. We included all adult patients
in the NCDB from 2004 to 2014 with a diagnosis of PCL
(International Classification of Diseases for Oncology, 3rd Edition SEER
Topography Codes C180‐2, C184, C186‐9, C199 with Histology
Code in Appendix 1). Exclusion criteria included stage IV disease,
patients operated on for palliative indications (as defined in the
NCDB), and surgery performed outside the reporting facility. The
primary exposure was the addition of adjuvant chemotherapy to
surgical resection, as defined by the NCDB.
2.3 | Outcomes
The primary outcome of this study was overall survival. Due to the
high rate of 90‐day mortality, comparisons were made only for
patients that survived 90 days. Secondary outcomes included R0
resection, 30 and 90‐day mortality. The NCDB does not capture
disease‐free survival.
2.4 | Covariates
Patient‐level variables included age, sex, race, and education and
income as markers of socioeconomic status. Comorbidities are
captured by the NCDB’s modification of the Charlson score,
which excludes the primary cancer diagnosis condition and then
reports the Charlson score as 0 (no comorbidities), 1 (total
Charlson score of 1) or 2 (total Charlson score of 2 or more).
Hospital‐level data collected included the cancer designation of
the hospital where the surgery was performed (community
cancer program, comprehensive community cancer program,
academic/research program). Type of PCL was also determined
using the International Classification of Diseases for Oncology, 3rd
Edition SEER Histology code. (Appendix 1). For the survival
analysis, marginal and follicular lymphoma were combined to
form a single category.
2.5 | Statistical analysis
Continuous and categorical data are expressed as mean with
standard deviation and proportions, with the exception of continuous
variables with grossly skewed distributions that are reported as the
median with the interquartile range. Continuous and categorical
variables were compared with the Student t test and the χ2 test,
respectively. For the survival analysis, the log‐rank test was used for
F IGURE 1 Flowchart of inclusion and exclusion criteria from the
National Cancer Database (NCDB)
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TABLE 1 Patient characteristics grouped by treatment with surgery alone (n = 1286) vs surgery with neoadjuvant or adjuvant chemotherapy
(n = 867)




(n = 867) P value
Age, median, y (IQR) 68 (56‐78) 71 (59‐81) 64 (52‐74) <.001
Female gender 769 (35.7%) 494 (38.4%) 275 (31.7%) .001
Race 0.70
White 1895 (88.0%) 1130 (87.9%) 765 (88.2%)
Black 137 (6.4%) 86 (6.7%) 51 (5.8%)
Asian/other 121 (5.6%) 70 (5.4%) 51 (5.9%)
Insurance type <.001
Private 784 (36.4%) 416 (32.3%) 368 (42.4%)
Medicare 1155 (53.6%) 751 (58.4%) 404 (46.6%)
Medicaid 91 (4.2%) 49 (3.8%) 42 (4.8%)
Other 56 (2.6%) 37 (2.9%) 19 (2.2%)
Uninsured 67 (3.1%) 33 (2.6%) 34 (3.9%)
Median household income by Zip Code .39
<$38 000 254 (12.2%) 215 (16.9%) 132 (15.5%)
$38 000‐$47 999 397 (19.1%) 308 (24.3%) 212 (24.8%)
$48 000‐62 999 565 (27.3%) 351 (27.7%) 219 (25.6%)
>$63 000 857 (41.3%) 394 (31.1%) 291 (34.1%)
Low education (>21% of adults not graduating from high school) 331 (15.4%) 203 (15.8%) 128 (14.7%) .51
Urban‐rural continuum .79
Metro 1699 (78.9%) 1015 (78.9%) 684 (78.9%)
Urban 412 (19.1%) 23 (1.8%) 19 (2.2%)
Rural 42 (1.9%) 248 (19.3%) 164 (18.9%)
Distance traveled, median, miles (IQR) 8 (3.6‐19.9) 7.5 (3.4‐19.1) 8.6 (4.0‐20.7) .06
Charlson score .11
0 1591 (73.9%) 932 (72.5%) 659 (76.0%)
1 394 (18.3%) 243 (18.9%) 151 (17.4%)
>1 168 (7.8%) 111 (8.6%) 57 (6.6%)
Facility .02
Community cancer program 635 (29.5%) 354 (27.5%) 281 (32.4%)
Comprehensive community cancer program 975 (45.3%) 609 (47.4%) 366 (42.2%)
Academic/research program 543 (25.2%) 323 (25.1%) 220 (25.4%)
Lymphoma subtype <.01
DLBCL 1228 (57.0%) 655 (50.9%) 573 (66.1%)
Burkitt 143 (6.6%) 56 (4.3%) 87 (10.0%)
Follicular 155 (7.2%) 107 (8.3%) 48 (5.5%)
Hodgkin 45 (2.1%) 34 (2.6%) 11 (1.3%)
Mantle Cell 76 (3.5%) 48 (3.7%) 28 (3.2%)
Marginal 243 (11.3%) 216 (16.8%) 27 (3.1%)
NHL NOS 110 (4.7%) 62 (4.8%) 48 (5.5%)
T‐cell 51 (2.4%) 32 (2.5%) 26 (3.0%)
Other 102 (4.7%) 76 (5.9%) 19 (2.2%)
Abbreviations: DLBCL, diffuse large B‐cell lymphoma; IQR, interquartile range; NHL, non‐Hodgkin lymphoma; NOS, not otherwise specified.
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bivariate comparison. All factors found to be significant for overall
survival in a bivariate analysis were compared using a multivariable
Cox proportional hazard model. All variables were initially consid-
ered using a backward Wald stepwise procedure with a P value of .20
to enter and .05 to eliminate variables. SAS statistical software
(version 9.3; SAS Institutes Inc, Cary NC) was used for all analyses.
All tests were two‐sided with an alpha level of .05.
3 | RESULTS
3.1 | Exposure and demographics
After applying exclusion criteria, a total of 2153 patients with PCL
who underwent surgery were identified in the NCDB from 2004 to
2014 (Figure 1 & Table 1). The median age was 68 (interquartile
range, 56‐78) and 769 (35.7%) were female. A total of 867 patients
(40.2%) underwent both surgery and adjuvant chemotherapy. The
majority of patients had a diffuse large B‐cell lymphoma (DLBCL)
subtype (57.0%) with marginal (10.3%) and follicular (7.2%) compris-
ing the top three subtypes. (Figure 2) Factors associated with the use
of adjuvant chemotherapy included younger age, male sex, private
insurance, treatment at a community cancer program, and DLBCL
subtype.
3.2 | Perioperative outcomes
Preoperative chemo‐ and radiotherapy were rarely administered
in this cohort, suggesting that the identified group of patients
represent a “surgery first” approach rather than treatment
failures. (Table 2). Overall, rates of R0 resection were relatively
low (54.2%) and were modestly higher in the surgery‐only cohort
(surgery+chemo 50.7% vs surgery 56.5%; P = .008). Postoperative
radiation was rarely administered (1.8% total). Rates of both 30
(5.6%) and 90‐day (11.1%) mortality were high. To further
F IGURE 2 Distribution of primary colonic lymphoma histologic
subtype. DLBCL, diffuse large B‐cell lymphoma; NHL, non‐Hodgkin
lymphoma; NOS, not otherwise specified [Color figure can be viewed
at wileyonlinelibrary.com]
TABLE 2 Treatment characteristics, short‐term outcomes, and overall survival of patients treated with surgery alone (n = 1286) vs with
surgery and chemotherapy (n = 867)
All (n = 2153) Surgery alone (n = 1286) Surgery+chemo (n = 867) P value
Preoperative chemotherapy 33 (1.5%) N/A 33 (3.8%)
Preoperative radiation 5 (0.2%) 1 (0.1%) 4 (0.4%) .07
R0 resection 1167 (54.2%) 727 (56.5%) 440 (50.7%) .008
Length of stay, d median (IQR) 6 (4‐9) 6 (4‐9) 6 (4‐8) .01
Postoperative chemotherapy 840 (39.0%) N/A 840 (96.9%)
Postoperative radiation 38 (1.8%) 18 (1.4%) 20 (2.3%) .11
30‐d readmission 143 (6.6%) 90 (7.0%) 53 (6.1%) .41
30‐d mortality 121 (5.6%) 108 (9.1%) 13 (1.6%) <.001
90‐d mortality 238 (11.1%) 197 (16.6%) 41 (5.0%) <.001
5‐yr overall survival (patients surviving 90 d) 71.8% 68.6% 75.4% .01
Abbreviation: IQR, interquartile range.
F IGURE 3 Kaplan‐Meier curve for overall survival stratified by
adjuvant chemotherapy [Color figure can be viewed at
wileyonlinelibrary.com]
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investigate the role of surgery in long term outcomes of PCL
patients, perioperative deaths were excluded.
3.3 | Overall survival
A total of 1915 (88.9%) patients survived 90 days and were included in
the analysis of overall survival. Over a mean follow up of 53 months, the
5‐year overall survival for the cohort was 71.8%. Thirty‐nine percent of
patients received adjuvant chemotherapy. The administration of
adjuvant chemotherapy was associated with improved 5‐year overall
survival (surgery + chemo 75.4%% vs surgery 68.6%; P = .01; Figure 3)
This relationship remained in a multivariate Cox proportional hazard
analysis that included age, Charlson comorbidity score and lymphoma
subtype (HR 1.22; 95% CI, 1.02‐1.45; P = .02; Table 3). R0 resection was
not associated with overall survival. An analysis of overall survival by
lymphoma subtype showed follicular/marginal lymphoma to be asso-
ciated with the best survival and T‐cell lymphoma to be associated with
the worst; Figure 4).
TABLE 3 Results of bivariate and multivariable Cox proportional hazards model analysis of patient, treatment, and tumor factors associated
with overall survival among 2153 primary colonic lymphoma patients
Overall survival Bivariate Multivariable
Variable HR (95% CI) P value HR (95% CI) P value
Surgery+chemo 1.24 (1.05‐1.47) .01 1.22 (1.02‐1.45) .02
Age
<40 REF REF
41‐51 0.50 (0.27‐0.92) .0281 0.40 (0.21‐0.77) .005
51‐60 0.51 (0.29‐0.90) .0205 0.40 (0.22‐0.73) .003
61‐70 0.33 (0.19‐0.57) <.0001 0.27 (0.15‐0.48) <.0001
70+ 0.13 (0.08‐0.23) <.0001 0.12 (0.06‐0.21) <.0001
R0 resection 0.95 (0.81‐1.12) .60
Female sex 1.05 (0.89‐1.25) .51
Caucasian 0.78 (0.59‐1.02) .07
Charlson score
0 REF REF
1 0.63 (0.52‐0.77) <.0001 0.72 (0.59‐0.89) .002
2+ 0.47 (0.36‐0.61) <.0001 0.62 (0.47‐0.81) <.0001
Facility
Community REF
Comprehensive 1.34 (1.10‐1.63) .002
Academic 0.93 (0.74‐1.18) .58
Lymphoma subtype
Follicular/marginal REF REF
DLBCL 0.58 (0.45‐0.74) <.0001 0.48 (0.37‐0.61) <.0001
Burkitt 0.83 (0.55‐1.26) .38 0.44 (0.29‐0.68) .0002
Mantle cell 0.55 (0.35‐0.83) .005 0.45 (0.29‐0.69) .0003
NHL NOS 0.51 (0.34‐0.78) .001 0.47 (0.30‐0.71) .0003
T‐cell 0.28 (0.17‐0.47) <.0001 0.27 (0.16‐0.44) <.0001
Other 0.45 (0.32‐0.64) <.0001 0.45 (0.32‐0.64) <.0001
Abbreviations: DLBCL, diffuse large B‐cell lymphoma; HR: hazard ratio; NHL, non‐Hodgkin lymphoma; NOS: not otherwise specified.
F IGURE 4 Kaplan‐Meier curve for overall survival stratified by
lymphoma subtype. DLBCL, diffuse large B‐cell lymphoma; NHL, non‐
Hodgkin lymphoma; NOS, not otherwise specified [Color figure can
be viewed at wileyonlinelibrary.com]
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4 | DISCUSSION
We present a modern cohort of 2153 nonmetastatic surgical PCL
patients undergoing nonpalliative resection. Our analyses reveal that
PCL patients suffer high short‐term mortality, have high rates of
margin positivity, and have an overall survival which is associated
with age, comorbid conditions, histologic subtype, and receipt of
adjuvant chemotherapy.
The older age and male predominance observed in our cohort are
similar to that reported in multiple studies across diverse patient
populations.5,11,12 Similarly, the preponderance of B‐cell lineage
tumors, in particular, DLBCL, is comparable to other reported series
of GI and colorectal lymphoma.4
In comparison to other large published series, our study
reflects modern care patterns and focuses on nonmetastatic
surgical patients. The largest study of PCL to date included 3342
patients collected from the Surveillance, Epidemiology, and End
Results (SEER) database, and demonstrated improved survival
among patients who underwent surgery.5 However, further
survival analyses demonstrated a benefit from surgery only among
early‐stage patients, patients with right‐sided tumors, and patients
with DLBCL. Patients with indolent lymphoma, left‐sided lesions,
and advanced disease did not experience a survival benefit of
surgery. Notably, however, more than 30% of patients in the study
were treated before the year 2000, 21% had stage IV disease, and
only 60% underwent surgery.
Unlike this and other reported series of PCL, our study focused only
on likely oncologically “good risk” patients, in that they received
nonpalliative surgery and that stage IV patients were excluded. However,
despite the exclusion criteria, analysis revealed a high rate of margin
positivity and a high 30‐ and 90‐day mortality. Only 54% of patients
achieved R0 resection. The deidentified nature of the database makes it
impossible to determine the reason for R1 resection, but these data have
implications for surgical planning and could provide a rationale for
condition of neoadjuvant therapy. R0 resection was not predictive of
overall survival but may have other implications for patients.
Both 30 and 90‐ day mortality was unexpectedly high in this
analysis, comparing unfavorably to published short‐term mortality
rates for surgical patients with other GI cancers.13 Potential
contributory factors include the advanced age of the patients and
comorbid conditions, although surgical and tumor‐specific factors
may also contribute. Although the nature of the database prohibits a
complete understanding of the high mortality rate, it should be
considered in operative planning and patient counseling.
Multivariable analysis identified age, Charlson score, lymphoma
histologic subtype, and receipt of adjuvant chemotherapy as
independent predictors of overall survival. Among these, administra-
tion of chemotherapy is the sole modifiable risk factor. Adjuvant
chemotherapy has previously been shown to be favorably associated
with overall survival.14 However only 39% of patients in this study
received it. The low rate of adjuvant chemotherapy usage may be due
to patient fitness, surgical complications, patient refusal, or failure to
offer chemotherapy after resection.
The low rates of neoadjuvant therapy in our study indicate that the
majority of surgical patients underwent a “surgery first” approach,
whether by selected treatment strategy or surgical urgency. Not included
in this study is the outcome of the heterogeneous population of patients
who undergo nonoperative therapy alone. When considering surgery vs
chemotherapy for a PCL patient, intestinal perforation, and hemorrhage
on chemotherapy is often a major concern. Recognition that this
complication is less frequently observed than previously expected15 has
led to a paradigm shift in the treatment of gastric lymphoma. Successful
employment of neoadjuvant chemo‐radiation has diminished the role of
surgery,16 allowing for organ preservation with equivalent survival
outcome.17 Given the high rate of margin positivity, high operative
mortality, and the low rate of adjuvant chemotherapy, consideration of
up‐front chemotherapy/radiation is warranted in PCL as well.
Our study has several limitations based on the number of variables
available for the analysis. We were reliant on the NCDB coding of
staging and metastatic disease. In addition, we lacked data on the type
of chemotherapy administered and some lymphoma‐specific variables
such as the International Prognostic Index. As we do not have reliable
data on decision‐making around chemotherapy administration, the
potential for selection bias exists in the overall survival analysis. It is
unclear whether the benefit we observe in adjuvant therapy is related
to the chemotherapy or merely the fitness to receive chemotherapy.
We attempted to address this by only including patients who survived
for 90 days in our survival analysis. Furthermore, the lack of coding of
urgent vs elective surgeries makes it impossible to determine the role of
acute lymphoma presentations.
5 | CONCLUSIONS
In summary, surgical patients with PCL who suffer high rates of short‐
term mortality, are likely to have R1 or R2 resections, and are relatively
unlikely to receive adjuvant therapy, although adjuvant chemotherapy
provides a clear survival benefit. Prognostication of surgical patient
outcome may be improved by these results: overall survival is
associated with age, comorbidity score, lymphoma subtype, and
administration of adjuvant chemotherapy. Despite the limitations of
the analysis, these data may assist physicians in surgical planning,
patient counseling, and designing further studies for this rare and
morbid malignancy.
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